Journal
EPILEPSY RESEARCH
Volume 127, Issue -, Pages 191-194Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.eplepsyres.2016.09.005
Keywords
Valproic acid; Epilepsy surgery; Drug resistant epilepsy; Hyperammonemia
Categories
Funding
- Center of excellence for epilepsy by department of biothechnology under ministry of science and technology, government of India [BT/01/COE/09/08]
Ask authors/readers for more resources
Valproic acid (VPA) has been associated with coagulation factors deficiency, platelet dysfunction and hemorrhagic complications. We investigated 169 patients with drug resistant epilepsy (DRE), who underwent surgery, to look for clinical implications of VPA associated bleeding problems. All patients had normal preoperative coagulation profile. VPA was a part of polytherapy in 54% of patients (Group A), however 46% patients were not on VPA (Group B). The groups were comparable with mean age of 17.3 +/- 10.3 years. Mean duration of surgery in group A and B were 255 +/- 70 and 250 +/- 60 min respectively (p = 0.26). Average blood loss in group A was 399 +/- 254 and 389 +/- 228 ml in group B. (p = 0.62). The percentage of total blood volume lost was 12.7% (Group A) and 17.7% (Group B) respectively (p = 0.7). There were no bleeding complications in either group. Hyperammonemic encephalopathy occurred in 4 patients postoperateively requiring withdrawal or dose reduction of VPA. No mortality was recorded. We conclude that VPA does not increase clinically relevant perioperative haemorrhagic complications in patients having normal coagulation screen and platelet counts. However, hyperammonemic encephalopathy is observed in 4% of patients in perioperative period, favorably responding to discontinuation of VPA. (C) 2016 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available